Q.01

How do I license IVD kits in India?

Every IVD kit in India needs a licence under the Medical Devices Rules, 2017 (MDR 2017). Which licence you need, and which authority issues it, depends on two things: the kit's risk class (A to D) and whether you will make it in India or import it. Class A/B kits made in India are licensed by the State Licensing Authority. Class C/D manufacture, and all imports of any class, go to the Central Licensing Authority, which is the DCGI at CDSCO [1][2]. If the kit is a "new IVD", you also need a separate CDSCO permission (Form MD-29) before any licence can be granted.

1. Confirm scope and risk class

  • Scope: "substances used for in vitro diagnosis" count as in vitro diagnostic medical devices under the Rules [3]. According to CDSCO's IVD FAQ, the Rules do not cover the following [4]:
    • research-use-only (RUO) products;
    • QC materials and food, water or environmental tests not meant for human or animal diagnosis;
    • instruments, equipment and software used with IVDs.
  • Who classifies: the Central Licensing Authority does, under rule 4(2) and First Schedule Part II, and publishes class-wise lists on the CDSCO website [5].
  • How the classes work [6][7]:
    • Class D: screening blood, tissue or organs for transmissible agents before transfusion or transplant; agents causing life-threatening disease with a high risk of spreading; ABO, Rh, Kell, Kidd and Duffy grouping.
    • Class C: STIs, cancer diagnosis, genetic testing, HIV/HCV viral load, prenatal screening, most self-tests and near-patient tests.
    • Class A: reagents for a specific examination, instruments and specimen containers.
    • Class B: everything else.
    • If more than one rule applies, the higher class applies.
  • Examples from CDSCO's IVD list: HIV test kits are Class D [8]; HIV viral load kits are Class C [9].

2. Check whether it is a "new IVD"

A new IVD is one not yet approved by the Central Licensing Authority for manufacture or import [10]. For these:

  • No licence without permission: no manufacturing or import licence of any class may be granted until you hold the Form MD-29 permission [11][12].
  • Clinical performance evaluation (CPE): the sponsor applies in Form MD-24 and receives Form MD-25 within 90 days [13]. The study must be approved by a registered ethics committee and registered with CTRI before the first participant is enrolled [14].
  • Foreign approvals do not replace the Indian study: CDSCO says approvals in the EU, UK, Australia, Canada, Japan or the USA do not exempt Class B, C or D new IVDs from CPE in India. For Class A, CPE may not be needed unless the Central Licensing Authority asks for it [15].
  • Permission: apply in Form MD-28 with the Part IV Fourth Schedule data. Permission is issued in Form MD-29 within 90 days, which can be extended by up to 30 days [16][17].

3A. Manufacturing in India

Class A / BClass C / D
AuthorityState Licensing AuthorityCentral Licensing Authority
Application formMD-3 (MD-4 for a loan licence)MD-7 (MD-8 for a loan licence)
Licence issuedMD-5 / MD-6MD-9 / MD-10
Site auditClass A: none before grant, notified body audit within 120 days after grant. Class B: notified body audit within 90 days of application, licence decision within 20 days of the audit reportCDSCO inspection after the 45-day document scrutiny, licence decision within 45 days of the inspection report

Sources for the table: [18][19][11]

What every manufacturer needs:

  • Quality system: a site that complies with the Fifth Schedule QMS.
  • Staff: qualified technical staff for manufacturing and for testing [11].
  • Dossier for Class B, C or D: a plant master file, an IVD device master file (Appendix III), an essential principles checklist, and a performance evaluation report from a CDSCO-designated or registered testing laboratory [20].
  • Testing laboratories: the June 2025 CDSCO list names approved laboratories by kit category; for HIV kits these include NIB Noida, ICMR-NARI and ICMR-NIV [21].

3B. Importing

  • Who applies: an authorised agent appointed by the overseas manufacturer through a power of attorney [2]. The agent must already hold a manufacturing licence or a wholesale licence [22]. CDSCO's FAQ also accepts an MD-42 sale registration [23].
  • Forms and timeline: apply in Form MD-14 to CDSCO; the licence is issued in Form MD-15 within 9 months [12]. An overseas site inspection is discretionary [12].
  • Documents [20]:
    • notarised site registration and free sale certificate from the country of origin;
    • notarised QMS certificate;
    • wholesale or manufacturing licence;
    • device and plant master files;
    • performance evaluation report.
  • Effect of the country of origin:
    • Free sale certificate from Australia, Canada, Japan, the EU or the USA: the licence "shall be granted" without a clinical investigation.
    • Other countries, Class A/B: published safety and performance data, or a clinical investigation in the country of origin, plus a free sale certificate from that country.
    • Other countries, Class C/D: a clinical investigation in India may be required [12].
  • Lot reports: you can file MD-14 with a performance evaluation report for one lot and an undertaking for the other two. The remaining two reports must be submitted before you sell in India [24].
  • More than one importer: several agents may hold licences for the same product, and each must apply separately [25].

4. Test licences and sale

  • Making samples: a test licence to manufacture small quantities is applied for in Form MD-12 and issued in MD-13. It lasts 3 years [22].
  • Importing samples: a test licence to import (MD-17) costs USD 100 [26].
  • Selling or distributing: you need either a wholesale licence or a registration certificate from the State Licensing Authority (apply in Form MD-41, issued in MD-42). The MD-41/MD-42 route was added by G.S.R. 754(E) on 30.09.2022 [27]. MD-42 is normally issued within 10 days [28].

5. Fees and validity (Second Schedule, original text)

ItemFee
Manufacturing, Class A/BINR 5,000 per site + INR 500 per distinct device
Manufacturing, Class C/DINR 50,000 per site + INR 1,000 per distinct device
Import, Class A/B IVDUSD 1,000 per site + USD 10 per distinct IVD
Import, Class C/D IVDUSD 3,000 per site + USD 500 per distinct IVD
Overseas site inspectionUSD 6,000
CPE permission / new IVD permissionINR 25,000 each

Sources for the table: [7][29][30]

  • Validity: manufacturing and import licences are valid in perpetuity, provided you pay a retention fee every five years [31][12].
  • Late payment:
    • Manufacturing licence: a 2% per month late fee for up to 180 days, after which it is deemed cancelled.
    • Import licence: a 2% per month late fee for up to 90 days, after which it is deemed cancelled.

The rule text I read is the original 2017 Gazette version. Some later amendments exist: I confirmed the 2022 fifth amendment (MD-41/MD-42). Also, a CDSCO circular of April 2023 says Class C/D inspections are due within 60 days of application, a time limit the original rule 21 does not state [32]. So check current fees and timelines on the CDSCO portal before you file.

Approach: I searched the Medical Devices Rules, 2017 (original Gazette text), CDSCO's risk-classified IVD list, the CDSCO IVD and medical device FAQs, and CDSCO public notices and circulars. A consolidated text of the Rules including all later amendments is not in the data I can search.

Q.02

What changes for imported kits?

For imported IVD kits, three things change compared with making them in India. CDSCO (the Central Licensing Authority) licenses every risk class, A to D. The applicant must be an Indian authorised agent, not the overseas manufacturer. And the kit's country of origin decides how much clinical evidence you need. On top of that, imports carry their own rules on post-grant reporting, label stickers and minimum remaining shelf life at the port.

Who licenses and who applies

  • Authority: the Central Licensing Authority handles imports of all IVD classes. The State Licensing Authority's role is limited to Class A/B manufacture and to sale and stocking [1].
  • Applicant: the authorised agent applies in Form MD-14 through the online portal. The agent must hold a manufacturing licence or a wholesale licence [22]. A power of attorney from the overseas manufacturer appoints the agent [23].
  • Post-market surveillance: the licence holder (the authorised agent) is responsible for it [33].

Evidence and site checks

  • Dossier: Fourth Schedule Parts I and II, plus Part III (Appendix I and III only), with the Second Schedule fee [25].
  • Quality system: you submit a QMS certificate under the Fourth Schedule. You do not need to show Fifth Schedule compliance the way an Indian site does [34].
  • Site inspection: there is no mandatory audit before grant. CDSCO "may" inspect the overseas site (rule 35), and you pay the inspection fee if it does [12]. Per the FAQ, the inspection can happen before or after grant [34].
  • Country of origin (rule 36) [12]:
    • Free sale certificate from Australia, Canada, Japan, the EU or the USA: the licence "shall be granted" without a clinical investigation.
    • Other countries, Class C/D: the licence "may be granted" after a clinical investigation in India. The IVD FAQ calls this clinical performance evaluation in India [24].
    • Other countries, Class A/B: you need published safety and performance data or a clinical investigation in the country of origin, plus that country's free sale certificate.
  • New IVDs: you need MD-29 permission before any import licence is granted [12]. Each importer must get its own approval; a later importer cannot rely on the first one's [33].
  • Lot reports: you can file with one lot's performance evaluation report and an undertaking for the other two. The remaining two reports must reach CDSCO before you sell in India [24].

Timeline, validity and adding products

  • Decision: MD-15 is granted or refused within nine months of application. You can appeal a refusal to the Central Government within 45 days [12].
  • Validity: the licence is valid in perpetuity if you pay the retention fee every five years, for each overseas site and each licensed device. The late-payment window is 90 days at 2% per month; after that the licence is deemed cancelled [12]. A manufacturing licence gets 180 days.
  • Adding products or sites (rule 34(4)): you apply again with the fee and documents for an additional site or an additional device [22][12].
    • Same site, same legal manufacturer: only the product fee is due, and the licence keeps its existing validity.
    • Different site: you pay the site fee plus the product fee, and the licence is issued with fresh validity [33].
  • Several importers of one kit: this is allowed [25]. A later agent files a reduced set:
    • MD-14 and a new power of attorney;
    • the free sale certificate and fees;
    • its wholesale, MD-42 or manufacturing licence;
    • the label and IFU;
    • a copy of the earlier agent's licence;
    • the manufacturer's undertaking that the device and plant master files are unchanged [23].

Duties after the licence is granted (rule 38)

  • Foreign regulatory action: within 15 days, report any market withdrawal, regulatory restriction, cancellation of authorisation or not-of-standard-quality finding in the country of origin or any other market. You must also stop dispatch and marketing immediately [12].
  • Changes to the product or dossier [12]:
    • Major changes (Sixth Schedule) need prior approval. If CDSCO does not reply within 60 days, the change is deemed approved.
    • Minor changes must be notified within 30 days.
  • Change in constitution of the agent or the overseas manufacturer: notify within 30 days and file a fresh MD-14 within 180 days. The old licence stays valid meanwhile [35].
  • Moving the actual manufacturing site: this also needs a fresh licence [23].
  • With each shipment: an invoice showing the name and quantity, and the package insert supplied when the kit is sold [35].

Label and shelf life at import

  • Label (rule 44(n)): if these details are not already printed, add them by sticker [36]:
    • the import licence number;
    • the importer's name and address;
    • the address of the actual manufacturing premises;
    • the date of manufacture.
  • Manufacturing licence number: imported devices are exempt from this label item (rule 44(m)) [36].
  • Stickering in practice: it may be done at the licensed warehouse [37]. The specimen label you submit should leave space for the sticker [38].
  • Minimum remaining shelf life on the date of import (rule 47) [36]:
Total shelf-life claimImport not allowed if remaining shelf life is below
Less than 90 days40%
90 days to 1 year50%
More than 1 year60%
  • Test-licence imports: CDSCO's FAQ says kits imported under a test licence for testing, demonstration or training may have less remaining shelf life than these minimums [24].

Samples, evaluation and training kits

  • Licence: apply in Form MD-16. CDSCO decides within 30 days, sets the quantity, and issues Form MD-17, valid for three years [35].
  • Conditions: use the kits only at the place named in the licence, keep import records, and export or destroy unused kits with notice to CDSCO [35].

Pending guidance

CDSCO published a draft "Guidance for Import of In-Vitro Diagnostic Medical Device" (No. CDSCO/IVD/GD/DRAFT/IMP/01/2026, dated 30.01.2026). It covers filing on the cdscomdonline and NSWS portals and was open for 15 days of comment [39]. I only have the notice page, not the guidance itself, and found no final version.

Approach: I searched the Medical Devices Rules, 2017 (original Gazette text, rules 34 to 47), CDSCO's IVD and medical device FAQs and their addenda, and CDSCO public notices. I did not use an older CDSCO FAQ written under the earlier Drugs and Cosmetics Rules (Form 10 import licences), because it predates the 2017 Rules.

Q.03